Yige Fu - Search Results

Year	Number of Results
2014	3
2019	4
2020	7
2021	4
2022	0

1

Stromal disruption facilitating invasion of a 'nano-arsenal' into the solid tumor.

Fu Y, Saraswat AL, Monpara J, Patel K. Fu Y, et al. Drug Discov Today. 2021 Nov 22:S1359-6446(21)00496-7. doi: 10.1016/j.drudis.2021.11.015. Online ahead of print. Drug Discov Today. 2021. PMID: 34823002 Review.

2

Process optimization of twin-screw melt granulation of fenofibrate using design of experiment (DoE).

Mamidi HK, Palekar S, Nukala PK, Mishra SM, Patki M, Fu Y, Supner P, Chauhan G, Patel K. Mamidi HK, et al. Among authors: fu y. Int J Pharm. 2021 Jan 25;593:120101. doi: 10.1016/j.ijpharm.2020.120101. Epub 2020 Dec 10. Int J Pharm. 2021. PMID: 33309834

3

Nanoformulation of PROteolysis TArgeting Chimera targeting 'undruggable' c-Myc for the treatment of pancreatic cancer.

Saraswat A, Patki M, Fu Y, Barot S, Dukhande VV, Patel K. Saraswat A, et al. Among authors: fu y. Nanomedicine (Lond). 2020 Aug;15(18):1761-1777. doi: 10.2217/nnm-2020-0156. Epub 2020 Jul 23. Nanomedicine (Lond). 2020. PMID: 32698663

4

M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells.

Wu ZX, Peng Z, Yang Y, Wang JQ, Teng QX, Lei ZN, Fu YG, Patel K, Liu L, Lin L, Zou C, Chen ZS. Wu ZX, et al. Front Oncol. 2020 May 12;10:674. doi: 10.3389/fonc.2020.00674. eCollection 2020. Front Oncol. 2020. PMID: 32477940 Free PMC article.

5

Folate Receptor-Targeted Albumin Nanoparticles Based on Microfluidic Technology to Deliver Cabazitaxel.

Meng F, Sun Y, Lee RJ, Wang G, Zheng X, Zhang H, Fu Y, Yan G, Wang Y, Deng W, Parks E, Kim BYS, Yang Z, Jiang W, Teng L. Meng F, et al. Among authors: fu y. Cancers (Basel). 2019 Oct 16;11(10):1571. doi: 10.3390/cancers11101571. Cancers (Basel). 2019. PMID: 31623082 Free PMC article.

6

Multi-dose oral abuse deterrent formulation of loperamide using hot melt extrusion.

Nukala PK, Palekar S, Patki M, Fu Y, Patel K. Nukala PK, et al. Among authors: fu y. Int J Pharm. 2019 Oct 5;569:118629. doi: 10.1016/j.ijpharm.2019.118629. Epub 2019 Aug 16. Int J Pharm. 2019. PMID: 31425818

7

Efavirenz nanomicelles loaded vaginal film (EZ film) for preexposure prophylaxis (PrEP) of HIV.

Patki M, Vartak R, Jablonski J, Mediouni S, Gandhi T, Fu Y, Cetindag E, Dave R, Valente ST, Patel K. Patki M, et al. Among authors: fu y. Colloids Surf B Biointerfaces. 2020 Oct;194:111174. doi: 10.1016/j.colsurfb.2020.111174. Epub 2020 Jun 6. Colloids Surf B Biointerfaces. 2020. PMID: 32540766

8

Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma.

Fu Y, Rathod D, Patel K. Fu Y, et al. Exp Cell Res. 2020 Nov 1;396(1):112275. doi: 10.1016/j.yexcr.2020.112275. Epub 2020 Sep 6. Exp Cell Res. 2020. PMID: 32898554

9

EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAF^V600E Mutated Parent- and Vemurafenib-Resistant Melanoma.

Fu Y, Rathod D, Abo-Ali EM, Dukhande VV, Patel K. Fu Y, et al. Pharmaceutics. 2019 Oct 1;11(10):504. doi: 10.3390/pharmaceutics11100504. Pharmaceutics. 2019. PMID: 31581483 Free PMC article.

10

Development of Dual ARV-825 and Nintedanib-Loaded PEGylated Nano-Liposomes for Synergistic Efficacy in Vemurafnib-Resistant Melanoma.

Fu Y, Saraswat A, Wei Z, Agrawal MY, Dukhande VV, Reznik SE, Patel K. Fu Y, et al. Pharmaceutics. 2021 Jul 1;13(7):1005. doi: 10.3390/pharmaceutics13071005. Pharmaceutics. 2021. PMID: 34371697 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results